房颤患者心房活检检出心房淀粉样变性的患病率与临床表现
本研究在578例非瓣膜性房颤消融术中行心房活检,385例另行右室活检,免疫组化分型。心房样本淀粉样沉积检出率7%(40例),其中25例为ATTR型;随年龄、左室肥厚及左房低电压区增加患病率升至20%-40%。右室活检13例(3%)阳性,26例心房阳性者中13例右室无沉积,提示淀粉样变局限于心房。
要点
- 房颤消融术中行心房活检可检出早期心脏淀粉样变性,患病率7%。
- 高龄、左室肥厚及左房低电压区者心房淀粉样变性患病率升至20%-40%。
- 部分心房淀粉样变性患者右室活检阴性,提示病变局限于心房。
核心结论
- 心房活检在7%的房颤消融患者中检出淀粉样沉积,可识别早期心脏淀粉样变性。
研究设计与样本
- 在578例非瓣膜性房颤消融术中行心房活检,其中385例另行右室活检,采用免疫组化鉴定淀粉样类型。
- 另设58例临床诊断心脏淀粉样变性患者作为临床CA组进行对照。
主要发现
- 心房样本中40例(7%)检出淀粉样沉积,其中25例为ATTR型。
- abio-CA组左室后壁厚度为11.3 ± 2.2 mm,薄于临床CA组的15.3 ± 4.6 mm(P < .001)。
- abio-CA组左室后壁厚度为11.3 ± 2.2 mm,厚于非CA组的9.6 ± 1.4 mm(P < .001)。
- abio-CA组低电压区(<0.5 mV)频率为45%,高于非CA组的13%(P < .001)。
- 右室活检13例(3%)检出淀粉样沉积,含11例ATTR和2例轻链型。
临床怎么用
- 对接受房颤消融的高龄、左室肥厚或左房低电压区患者,可考虑心房活检以早期识别心脏淀粉样变性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: This study aimed to assess the prevalence of cardiac amyloidosis (CA) in patients with non-valvular atrial fibrillation (AF) and to test the hypothesis that early-stage CA can be identified through atrial biopsy. METHODS: Atrial biopsy was performed on 578 patients during AF ablation, with right ventricular (RV) biopsy conducted in 385 patients. The amyloid type was assessed using immunohistochemistry. Patients were classified into groups of atrial biopsy-detected CA (abio-CA) and non-CA, with an additional 58 patients clinically diagnosed with CA comprising the clinical CA group. RESULTS: Amyloid deposits were identified in atrial samples from 40 patients (7%), including 25 amyloid transthyretin (ATTR) types. Prevalence increased to 20%-40% with advancing age, left ventricular (LV) hypertrophy, and the presence of low-voltage areas in the left atrium. The abio-CA group exhibited a thinner LV posterior wall (11.3 ± 2.2 vs 15.3 ± 4.6 mm, P < .001) compared with the clinical CA group. The abio-CA group displayed a thicker LV posterior wall (11.3 ± 2.2 vs 9.6 ± 1.4 mm, P < .001) and a higher frequency of low-voltage areas defined as <0.5 mV (45% vs 13%, P < .001) compared with the non-CA group. Right ventricular biopsy identified amyloid deposits in 13 patients (3%), comprising 11 ATTR and 2 light-chain types. Among the 26 patients in the abio-CA group who underwent RV biopsy, 13 had no amyloid deposits in RV samples, indicating confined atrial amyloidosis. CONCLUSIONS: Atrial biopsy revealed amyloid deposits in 7% of patients undergoing AF ablation, identifying early-stage CA.
引用
- Shinzato K, Takahashi Y, Yamaguchi T, et al. Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation. Eur Heart J. 2025. PMID: 40392565. doi:10.1093/eurheartj/ehaf332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。